|
Jinan Hong Kongda Chemical Co.,Ltd
|
Jinan Hongkangda Chemical Co., Ltd. is a technology-driven enterprise specializing in the production of chemical raw materials and advanced pharmaceutical intermediates, integrating scientific research, production and sales. The company is headquartered in Jinan, as the capital of Shandong Province, China's largest pharmaceutical province, has strong resource advantages.
The company has a complete production system, with more than 150 sets of reaction equipment, covering high temperature, ultra-low temperature and hydrogenation and other special reaction production facilities. Equipped with an experienced R & D team, and with a number of institutions, research institutes to establish long-term stable cooperative relations, in order to continue to innovate, optimize the process.
In order to optimize global resources, protect the environment and make up for the shortage of some domestic chemical intermediates, the company has set up a cooperation center in India to develop domestic shortage varieties, and has established stable cooperative relations with a number of Indian enterprises over the years to solve the problem of supply shortage of some products. |
Send Inquiry
|
|
Aarambh Life Science
|
| PHARMACOPEA |
USP/BP/EP |
| CAS NUMBER |
71125-38-7 |
| THERAPEUTIC USE |
ANTI- INFLAMMATORY |
| PACKING |
25kgs HDPE DRUMS |
| SOURCE / ROUTE OF PRODUCT |
SYNTHETIC |
| DESCRIPTION / PHYSICAL APPEARANCE |
Pale yellow coloured powder |
| MOLECULAR FORMULA |
C14H13N3O4S2 |
Summary:
Meloxicam is a Nonsteroidal Anti-Inflammatory medication used to treat pain and inflammation in rheumatic diseases and osteoarthritis. Meloxicam is used to relieve pain, tenderness, swelling, and stiffness caused by osteoarthritis (arthritis caused by a breakdown of the lining of the joints) and rheumatoid arthritis (arthritis caused by swelling of the lining of the joints)
USE in Human:
Meloxicam a Nonsteroidal Anti-Inflammatory drug (NSAID) is used in Tablets and Injections |
Send Inquiry
|
Pharma Sources Insight January 2025
